Sildenafil
Brand names: Viagra, Revatio (PAH)
Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction and, in other formulations, pulmonary arterial hypertension.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively inhibits PDE5, the enzyme that breaks down cyclic GMP, thereby enhancing nitric oxide-mediated smooth muscle relaxation and increasing blood flow into the corpus cavernosum during sexual stimulation.
Prescribing in practice
- It is absolutely contraindicated with nitrates or nicorandil because the combination can cause profound, potentially fatal hypotension.
- It should be avoided or used with caution in recent stroke or myocardial infarction, significant cardiovascular disease and severe hepatic impairment.
- Caution and dose consideration apply with alpha-blockers and potent CYP3A4 inhibitors owing to additive hypotension and increased exposure.
Monitoring
Assess cardiovascular fitness for sexual activity before prescribing and review efficacy and tolerability rather than relying on routine laboratory monitoring.
Counselling the patient
- Never take this with nitrate heart medicines or recreational nitrates ('poppers').
- Seek urgent medical help for an erection lasting several hours or for sudden loss of vision or hearing.
- It works only with sexual stimulation and a high-fat meal can delay its onset.
Evidence & guidelines
Sildenafil is an established first-line PDE5 inhibitor for erectile dysfunction; see NICE guidance and the SPC for indications and cautions.
Reference: NICE NG215 Erectile Dysfunction; ESC PAH Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia